Commonwealth Equity Services LLC trimmed its position in Cencora by 7.9% during the third quarter, offloading 3,580 shares and reducing its holding to 41,656 shares valued at roughly $13.0 million as of quarter-end. This move follows a broader trend of portfolio rebalancing among institutional investors, with Salomon & Ludwin LLC boosting its position by 638.1% and Atlantic Edge Private Wealth Management increasing its stake by 70.0% over the same period. Despite these shifts, Cencora remains institutionally owned at 97.5%, suggesting that large investors continue to view the company as a core holding but are fine-tuning their allocations in response to sector dynamics and valuation considerations.

In its latest quarterly report, Cencora delivered revenue of $83.73 billion, up 5.9% year-over-year, and non-GAAP earnings per share of $3.84, exceeding consensus by $0.05. The company’s net margin stood at 0.48% and return on equity at an impressive 227.15%, reflecting efficient capital deployment in its distribution and specialty pharmacy segments. Management also announced a 9.1% increase to the quarterly dividend, raising it to $0.60 per share, marking the sixth consecutive annual dividend hike. This payout represents an annualized yield of approximately 0.7% and a payout ratio near 30%, underscoring Cencora’s commitment to returning cash to shareholders while maintaining investment capacity for strategic initiatives.

Wall Street sentiment on Cencora remains constructive, with recent upgrades from JPMorgan Chase & Co., TD Cowen and Wells Fargo, raising their price targets to the $392–417 range and collectively assigning an “overweight” or “buy” bias. These analysts point to the company’s market leadership in pharmaceutical distribution, accelerating specialty growth and robust free cash flow conversion. Concurrently, two executive vice presidents executed share sales totaling over 5,000 shares at average prices in the mid-$340s range, realizing proceeds of approximately $1.7 million. While insiders have reduced their holdings by 12.3% and 8.2% respectively, the transactions represent routine portfolio diversification rather than a shift in strategic outlook.